Finally, although SGLT2 inhibitors are extensively studied in diabetic CKD, their efficacy and safety in non-diabetic, non-hypertensive CKD patients prone to kidney stones remain largely untested. This evidence concerns the gene SLC5A2 and chronic kidney disease.